|
Gene: NDUFA1 |
Gene summary for NDUFA1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | NDUFA1 | Gene ID | 4694 |
Gene name | NADH:ubiquinone oxidoreductase subunit A1 | |
Gene Alias | CI-MWFE | |
Cytomap | Xq24 | |
Gene Type | protein-coding | GO ID | GO:0006091 | UniProtAcc | O15239 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
4694 | NDUFA1 | CA_HPV_1 | Human | Cervix | CC | 7.22e-07 | 1.40e-02 | 0.0264 |
4694 | NDUFA1 | CA_HPV_3 | Human | Cervix | CC | 1.67e-05 | -1.04e-01 | 0.0414 |
4694 | NDUFA1 | N_HPV_2 | Human | Cervix | N_HPV | 4.74e-02 | 1.43e-01 | -0.0131 |
4694 | NDUFA1 | CCI_1 | Human | Cervix | CC | 9.77e-16 | -9.33e-01 | 0.528 |
4694 | NDUFA1 | CCI_2 | Human | Cervix | CC | 1.25e-08 | -6.09e-01 | 0.5249 |
4694 | NDUFA1 | CCI_3 | Human | Cervix | CC | 7.17e-23 | -9.66e-01 | 0.516 |
4694 | NDUFA1 | CCII_1 | Human | Cervix | CC | 3.67e-38 | -1.01e+00 | 0.3249 |
4694 | NDUFA1 | Tumor | Human | Cervix | CC | 2.41e-03 | 2.80e-01 | 0.1241 |
4694 | NDUFA1 | H2 | Human | Cervix | HSIL_HPV | 8.24e-03 | -3.03e-01 | 0.0632 |
4694 | NDUFA1 | L1 | Human | Cervix | CC | 8.47e-08 | -2.32e-01 | 0.0802 |
4694 | NDUFA1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.76e-46 | 9.65e-01 | 0.0155 |
4694 | NDUFA1 | HTA11_2487_2000001011 | Human | Colorectum | SER | 2.12e-56 | 1.82e+00 | -0.1808 |
4694 | NDUFA1 | HTA11_2951_2000001011 | Human | Colorectum | AD | 1.82e-11 | 9.62e-01 | 0.0216 |
4694 | NDUFA1 | HTA11_1938_2000001011 | Human | Colorectum | AD | 8.39e-50 | 1.72e+00 | -0.0811 |
4694 | NDUFA1 | HTA11_78_2000001011 | Human | Colorectum | AD | 1.99e-10 | 5.94e-01 | -0.1088 |
4694 | NDUFA1 | HTA11_347_2000001011 | Human | Colorectum | AD | 7.77e-81 | 1.78e+00 | -0.1954 |
4694 | NDUFA1 | HTA11_411_2000001011 | Human | Colorectum | SER | 1.02e-24 | 1.98e+00 | -0.2602 |
4694 | NDUFA1 | HTA11_2112_2000001011 | Human | Colorectum | SER | 8.53e-24 | 2.02e+00 | -0.2196 |
4694 | NDUFA1 | HTA11_3361_2000001011 | Human | Colorectum | AD | 8.14e-42 | 1.42e+00 | -0.1207 |
4694 | NDUFA1 | HTA11_83_2000001011 | Human | Colorectum | SER | 5.14e-41 | 1.77e+00 | -0.1526 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00060918 | Breast | Precancer | generation of precursor metabolites and energy | 94/1080 | 490/18723 | 1.54e-25 | 1.64e-22 | 94 |
GO:00971939 | Breast | Precancer | intrinsic apoptotic signaling pathway | 59/1080 | 288/18723 | 8.07e-18 | 3.60e-15 | 59 |
GO:20012339 | Breast | Precancer | regulation of apoptotic signaling pathway | 65/1080 | 356/18723 | 7.70e-17 | 3.17e-14 | 65 |
GO:20012429 | Breast | Precancer | regulation of intrinsic apoptotic signaling pathway | 41/1080 | 164/18723 | 6.48e-16 | 2.31e-13 | 41 |
GO:00229008 | Breast | Precancer | electron transport chain | 42/1080 | 175/18723 | 1.37e-15 | 4.59e-13 | 42 |
GO:00525479 | Breast | Precancer | regulation of peptidase activity | 71/1080 | 461/18723 | 2.72e-14 | 6.94e-12 | 71 |
GO:00525489 | Breast | Precancer | regulation of endopeptidase activity | 67/1080 | 432/18723 | 1.06e-13 | 2.36e-11 | 67 |
GO:20001169 | Breast | Precancer | regulation of cysteine-type endopeptidase activity | 43/1080 | 235/18723 | 1.30e-11 | 1.83e-09 | 43 |
GO:00068398 | Breast | Precancer | mitochondrial transport | 45/1080 | 254/18723 | 1.37e-11 | 1.88e-09 | 45 |
GO:00432819 | Breast | Precancer | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 40/1080 | 209/18723 | 1.59e-11 | 2.07e-09 | 40 |
GO:00102578 | Breast | Precancer | NADH dehydrogenase complex assembly | 19/1080 | 57/18723 | 1.93e-10 | 1.92e-08 | 19 |
GO:00329818 | Breast | Precancer | mitochondrial respiratory chain complex I assembly | 19/1080 | 57/18723 | 1.93e-10 | 1.92e-08 | 19 |
GO:00331088 | Breast | Precancer | mitochondrial respiratory chain complex assembly | 24/1080 | 93/18723 | 3.39e-10 | 3.16e-08 | 24 |
GO:20012349 | Breast | Precancer | negative regulation of apoptotic signaling pathway | 39/1080 | 224/18723 | 5.35e-10 | 4.77e-08 | 39 |
GO:20012439 | Breast | Precancer | negative regulation of intrinsic apoptotic signaling pathway | 23/1080 | 98/18723 | 5.82e-09 | 4.45e-07 | 23 |
GO:00458629 | Breast | Precancer | positive regulation of proteolysis | 51/1080 | 372/18723 | 7.77e-09 | 5.70e-07 | 51 |
GO:00109529 | Breast | Precancer | positive regulation of peptidase activity | 33/1080 | 197/18723 | 3.01e-08 | 1.89e-06 | 33 |
GO:00432808 | Breast | Precancer | positive regulation of cysteine-type endopeptidase activity involved in apoptotic process | 24/1080 | 129/18723 | 3.13e-07 | 1.50e-05 | 24 |
GO:00109509 | Breast | Precancer | positive regulation of endopeptidase activity | 29/1080 | 179/18723 | 4.23e-07 | 1.90e-05 | 29 |
GO:20010568 | Breast | Precancer | positive regulation of cysteine-type endopeptidase activity | 25/1080 | 148/18723 | 1.19e-06 | 4.60e-05 | 25 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0520814 | Liver | NAFLD | Chemical carcinogenesis - reactive oxygen species | 44/1043 | 223/8465 | 9.22e-04 | 1.31e-02 | 1.06e-02 | 44 |
hsa0493214 | Liver | NAFLD | Non-alcoholic fatty liver disease | 33/1043 | 155/8465 | 1.04e-03 | 1.42e-02 | 1.14e-02 | 33 |
hsa0520815 | Liver | NAFLD | Chemical carcinogenesis - reactive oxygen species | 44/1043 | 223/8465 | 9.22e-04 | 1.31e-02 | 1.06e-02 | 44 |
hsa0493215 | Liver | NAFLD | Non-alcoholic fatty liver disease | 33/1043 | 155/8465 | 1.04e-03 | 1.42e-02 | 1.14e-02 | 33 |
hsa0501214 | Liver | Cirrhotic | Parkinson disease | 158/2530 | 266/8465 | 3.62e-24 | 6.02e-22 | 3.71e-22 | 158 |
hsa0493222 | Liver | Cirrhotic | Non-alcoholic fatty liver disease | 106/2530 | 155/8465 | 2.16e-23 | 2.40e-21 | 1.48e-21 | 106 |
hsa0501614 | Liver | Cirrhotic | Huntington disease | 172/2530 | 306/8465 | 1.65e-22 | 1.10e-20 | 6.77e-21 | 172 |
hsa0502014 | Liver | Cirrhotic | Prion disease | 152/2530 | 273/8465 | 1.84e-19 | 8.78e-18 | 5.41e-18 | 152 |
hsa0501414 | Liver | Cirrhotic | Amyotrophic lateral sclerosis | 187/2530 | 364/8465 | 1.56e-18 | 6.50e-17 | 4.01e-17 | 187 |
hsa0019014 | Liver | Cirrhotic | Oxidative phosphorylation | 83/2530 | 134/8465 | 1.03e-14 | 3.44e-13 | 2.12e-13 | 83 |
hsa0520822 | Liver | Cirrhotic | Chemical carcinogenesis - reactive oxygen species | 121/2530 | 223/8465 | 1.35e-14 | 4.08e-13 | 2.52e-13 | 121 |
hsa0502214 | Liver | Cirrhotic | Pathways of neurodegeneration - multiple diseases | 217/2530 | 476/8465 | 7.30e-14 | 2.03e-12 | 1.25e-12 | 217 |
hsa0501014 | Liver | Cirrhotic | Alzheimer disease | 180/2530 | 384/8465 | 5.52e-13 | 1.36e-11 | 8.36e-12 | 180 |
hsa0471414 | Liver | Cirrhotic | Thermogenesis | 121/2530 | 232/8465 | 5.70e-13 | 1.36e-11 | 8.36e-12 | 121 |
hsa0541514 | Liver | Cirrhotic | Diabetic cardiomyopathy | 108/2530 | 203/8465 | 1.99e-12 | 4.41e-11 | 2.72e-11 | 108 |
hsa0472314 | Liver | Cirrhotic | Retrograde endocannabinoid signaling | 57/2530 | 148/8465 | 1.45e-02 | 4.39e-02 | 2.71e-02 | 57 |
hsa0501215 | Liver | Cirrhotic | Parkinson disease | 158/2530 | 266/8465 | 3.62e-24 | 6.02e-22 | 3.71e-22 | 158 |
hsa0493232 | Liver | Cirrhotic | Non-alcoholic fatty liver disease | 106/2530 | 155/8465 | 2.16e-23 | 2.40e-21 | 1.48e-21 | 106 |
hsa0501615 | Liver | Cirrhotic | Huntington disease | 172/2530 | 306/8465 | 1.65e-22 | 1.10e-20 | 6.77e-21 | 172 |
hsa0502015 | Liver | Cirrhotic | Prion disease | 152/2530 | 273/8465 | 1.84e-19 | 8.78e-18 | 5.41e-18 | 152 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NDUFA1 | SNV | Missense_Mutation | novel | c.115N>A | p.Ala39Thr | p.A39T | O15239 | protein_coding | deleterious(0.05) | probably_damaging(0.998) | TCGA-A7-A4SE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
NDUFA1 | SNV | Missense_Mutation | c.22G>A | p.Gly8Arg | p.G8R | O15239 | protein_coding | tolerated(0.06) | probably_damaging(1) | TCGA-AN-A04A-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
NDUFA1 | SNV | Missense_Mutation | c.130N>A | p.His44Asn | p.H44N | O15239 | protein_coding | deleterious(0.02) | benign(0.009) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD | |
NDUFA1 | SNV | Missense_Mutation | rs780641472 | c.175N>T | p.Arg59Cys | p.R59C | O15239 | protein_coding | tolerated(0.21) | benign(0.005) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
NDUFA1 | SNV | Missense_Mutation | novel | c.85N>C | p.Phe29Leu | p.F29L | O15239 | protein_coding | tolerated(0.21) | benign(0.164) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
NDUFA1 | SNV | Missense_Mutation | rs746256856 | c.176N>A | p.Arg59His | p.R59H | O15239 | protein_coding | tolerated(0.42) | benign(0.005) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
NDUFA1 | SNV | Missense_Mutation | c.112G>A | p.Val38Ile | p.V38I | O15239 | protein_coding | tolerated(0.65) | benign(0) | TCGA-D1-A101-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
NDUFA1 | SNV | Missense_Mutation | c.112N>T | p.Val38Phe | p.V38F | O15239 | protein_coding | tolerated(0.1) | benign(0.003) | TCGA-EY-A1GV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | carboplatin | SD | |
NDUFA1 | SNV | Missense_Mutation | novel | c.36N>T | p.Met12Ile | p.M12I | O15239 | protein_coding | tolerated(0.24) | benign(0.199) | TCGA-05-4396-01 | Lung | lung adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
NDUFA1 | SNV | Missense_Mutation | c.135N>C | p.Trp45Cys | p.W45C | O15239 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-55-7283-01 | Lung | lung adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | carboplatin | PR |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4694 | NDUFA1 | ENZYME | inhibitor | CHEMBL1703 | METFORMIN HYDROCHLORIDE | |
4694 | NDUFA1 | ENZYME | inhibitor | CHEMBL3545320 | ME-344 | |
4694 | NDUFA1 | ENZYME | inhibitor | CHEMBL3545135 | NV-128 |
Page: 1 |